BioPharma
Sanofi Secures Global Rights to Rovadicitinib in $1.53B Deal
Sanofi has committed up to $1.53 billion to obtain global rights to a novel therapy from Sino Biopharmaceutical, adding a first-in-class JAK/ROCK inhibitor to its hematology and immunology pipeline. The French pharmaceutical group will make an upfront payment of...
Business & Industry
UK Invests £47.8M to Expand NHS Clinical Trial Capacity
The UK government has announced nearly £50 million in funding aimed at strengthening the NHS’s capacity to conduct commercial research projects and clinical trials supported partly by the pharmaceutical industry. The investment is intended to supply critical research and...
Business & Industry
CMS Extends GENEROUS MFN Drug Pricing Deadline to April
The Centers for Medicare & Medicaid Services (CMS) in the US has moved to extend the enrolment window for its GENEROUS pilot programme, an initiative aimed at introducing most-favoured-nation (MFN) pricing for outpatient drugs reimbursed by Medicaid. The agency...
Business & Industry
Lilly Launches New AI Supercomputer for Drug Development
Eli Lilly has launched what it describes as the most powerful AI factory wholly owned and operated by a pharmaceutical company, marking a significant expansion of advanced computing infrastructure in life sciences. The system, named LillyPod, was inaugurated in...
News
Periodontal Disease as a Modifiable Risk Factor in Systemic Conditions
Periodontal disease has long been viewed primarily as a localized oral condition affecting the supporting structures of the teeth.
However, growing evidence suggests that its impact extends well beyond the oral cavity.
Chronic periodontal inflammation is increasingly recognized as a potential...
News
How Pharma is Navigating EPR’s Split-Tier Reality in 2026 without Losing Regulatory Sterility
In 2026, the Pharmaceutical and Medical Device sectors face a "split-tier" EPR reality. Unlike general consumer goods, pharma has specific exemptions and unique traps that redefine how you handle your regulatory infrastructure for this niche. By leveraging the insights...
Business & Industry
Novo Nordisk and Vivtex Sign Strategic Oral Biologics Deal
Novo Nordisk and Vivtex have formalised a collaboration aimed at advancing next-generation oral biologic therapies targeting obesity, diabetes and related comorbidities.
Under the terms of the agreement, Vivtex will grant Novo Nordisk licences to selected oral drug-delivery technologies. In return,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read